RealCold Acquires SCL, Betting Big on Pharmaceutical Logistics

LAKELAND, Fla. and DALLAS – May 27, 2026 – In a decisive move that reshapes its strategic focus, national cold chain provider RealCold announced today its acquisition of SCL Cold Chain, a Dallas-based logistics firm renowned for its specialized expertise in handling temperature-sensitive pharmaceuticals. The deal marks RealCold's formal entry into the high-growth, heavily regulated pharmaceutical logistics market, diversifying its portfolio beyond its established dominance in the food sector.

Founded in just 2022, RealCold has aggressively expanded its footprint across the United States, building a network of over 61 million cubic feet of temperature-controlled space. This acquisition, however, is not merely about adding volume. It represents a strategic pivot, integrating SCL's highly specialized, CEIV Pharma-certified capabilities into RealCold's rapidly scaling national infrastructure. SCL will continue to operate under its current name as a distinct unit within the RealCold organization.

A Strategic Pivot from Food to Pharma

RealCold has built its reputation on engineering bespoke cold chain solutions for the food industry, serving producers, retailers, and distributors. Backed by a $1 billion investment commitment from affiliate Related Fund Management (RFM), the company has been on a fast track, developing massive, state-of-the-art facilities in key logistics hubs like Lakeland, Florida; Lockhart, Texas; and East Hanover, New Jersey. This infrastructure was designed to provide 1-to-2-day ground service for the majority of U.S. consumers, primarily for food and e-commerce fulfillment.

The acquisition of SCL Cold Chain signals a deliberate expansion of that mission. SCL brings a different kind of expertise: the meticulous, high-consequence logistics required for pharmaceuticals, biologics, and medical devices. This includes FDA-registered facilities, rigorous continuous temperature monitoring, and a proven end-to-end chain of custody—capabilities that are non-negotiable for global pharmaceutical leaders.

RealCold CEO Keith Goldsmith emphasized that the move was driven by a rare alignment of operational philosophy. "From our first conversations with the SCL team, it was clear that they had accomplished something exceptional: they built genuine expertise in a highly specialized and demanding vertical while maintaining exactly the customer-centric mindset that RealCold is known for," Goldsmith commented. "This transaction goes beyond an acquisition of capabilities; it is an alignment of values, culture, and vision. With RealCold's capital, national network, and platform, we are positioned to scale SCL's capabilities to serve the world's leading pharmaceutical companies in ways that were not previously possible."

Tapping a High-Stakes, High-Growth Market

The timing of RealCold's entry into pharma logistics is critical. The global cold chain logistics market is projected to surge to over $862 billion by 2032, propelled by the booming biologics and vaccine sectors. These advanced medical products are often highly sensitive to temperature fluctuations, making a secure and verifiable cold chain not just a logistical preference but a matter of patient safety and regulatory compliance.

This is where SCL's credentials become the crown jewel of the acquisition. The company holds the prestigious CEIV (Center of Excellence for Independent Validators) Pharma certification, one of the most demanding accreditations in the industry, which validates its ability to handle sensitive medical products to the highest global standards. This, combined with its status as an FDA-registered and Bonded CFS (Customs Freight Station) facility, provides the regulatory rigor that major pharmaceutical manufacturers demand.

By acquiring this expertise, RealCold bypasses the years it would take to build such a reputation and compliance framework from scratch. It immediately gains credibility in a market where trust and proven performance are paramount.

Forging a National Pharma Logistics Powerhouse

The synergy between the two companies creates a formidable new competitor in the specialized logistics landscape. SCL, previously a regional expert centered in Dallas-Fort Worth, now has access to RealCold's national network and significant capital resources. This fusion allows SCL's specialized services to be deployed on a national scale, a prospect that its president, Bryan Severin, described as transformative.

"We have spent considerable time building something differentiated in the pharmaceutical cold chain, a service that merges operational rigor, an experienced team, and above all, the trust of our clients," Severin said. "The opportunity to bring those capabilities to a national audience through RealCold's platform is extraordinary. The demand for compliant, end-to-end pharma cold chain is enormous, and we are now positioned to meet it at scale."

This new entity is poised to challenge established players like DHL and FedEx Healthcare by offering a unique combination of specialized, pharma-certified operations and a modern, rapidly expanding physical footprint. For pharmaceutical clients, this means a new option for a resilient, compliant national partner capable of ensuring the integrity of medications, vaccines, and critical clinical trial materials from coast to coast. At the same time, RealCold's existing food and beverage customers gain access to an even more robust network with enhanced capabilities, underscoring a broader industry trend where the lines between specialized logistics sectors are beginning to blur. The complex infrastructure required for one high-value, temperature-sensitive good can often be adapted for another, creating powerful economies of scale for providers who can master multiple verticals.